Clinical Trials ArenaOriginal article
BioNTech misses PFS endpoints in Phase II/III cancer vaccine trial
Phase 2negativeNegative
AI Analysis
Summary
BioNTech's Phase II/III cancer vaccine trial missed its primary PFS endpoint, though the company still has potential for success with OS outcomes.
Clinical Trial Data
Phase
II/III
Primary Endpoint
Not Met
Outcome Details
PFS endpoint not achieved
Importance:7/10
Sentiment:
-0.65
oncologycancer vaccineclinical trialendpoint miss
Related Companies
Read the original article
Published by Clinical Trials Arena on October 13, 2026 3:01 PM